T2 Biosystems (NASDAQ:TTOO) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of T2 Biosystems (NASDAQ:TTOO) to a sell rating in a research note issued to investors on Tuesday morning.

Separately, Canaccord Genuity Group upped their price target on T2 Biosystems from $3.00 to $5.00 and gave the stock a hold rating in a research report on Tuesday.

T2 Biosystems Stock Performance

Shares of TTOO stock opened at $4.89 on Tuesday. T2 Biosystems has a 52 week low of $2.60 and a 52 week high of $70.00. The company’s 50 day moving average price is $5.09 and its two-hundred day moving average price is $4.48.

T2 Biosystems (NASDAQ:TTOO) last posted its quarterly earnings data on Monday, July 29th. The medical equipment provider reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.31. The company had revenue of $1.95 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in T2 Biosystems stock. Virtu Financial LLC increased its stake in T2 Biosystems, Inc. (NASDAQ:TTOO) by 29.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,096 shares of the medical equipment provider’s stock after buying an additional 3,018 shares during the quarter. Virtu Financial LLC owned approximately 0.24% of T2 Biosystems worth $39,000 as of its most recent SEC filing. 23.18% of the stock is owned by institutional investors.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.